Stonepine Capital Management, LLC Portfolio Holdings

Stonepine Capital Management, LLC

  • $124 Billion
  • Q4 2024

Stonepine Capital Management, LLC has filed its 13F form on February 13, 2025 for Q4 2024 where it was disclosed a total value porftolio of $124 Billion distributed in 52 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Adma Biologics, Inc. with a value of $21.3B, Evolus, Inc. with a value of $14B, Tela Bio, Inc. with a value of $7.11B, Galapagos Nv with a value of $5.5B, and Kempharm, Inc with a value of $4.98B.

Examining the 13F form we can see an decrease of $34.4B in the current position value, from $158B to 124B.

Stonepine Capital Management, LLC is based out at Bend, OR

Below you can find more details about Stonepine Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $124 Billion
Healthcare: $98.8 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$3.34B
$21.3 Billion 17.18% of portfolio
1,241,032
Q4 2024 Reduced 33.63%
$805M
$14 Billion 11.27% of portfolio
1,264,651
Q4 2024 Reduced 7.68%
$43.3M
$7.11 Billion 5.74% of portfolio
2,353,099
Q4 2024 Added 111.99%
$1.69B
$5.5 Billion 4.44% of portfolio
200,000
Q4 2024 Reduced 58.22%
$170M
$4.98 Billion 4.02% of portfolio
597,700
Q4 2024 Reduced 14.61%
Verastem Inc
-
$4.5 Billion 3.63% of portfolio
-
Q4 2024 Reduced 33.6%
$2.96B
$4.04 Billion 3.26% of portfolio
220,000
Q4 2024 Added 11.73%
$246M
$3.92 Billion 3.17% of portfolio
238,222
Q4 2024 Added 25.84%
Optinose Inc
-
$3.93 Billion 3.17% of portfolio
-
Q4 2024 New
Indivior PLC
-
$3.79 Billion 3.06% of portfolio
-
Q4 2024 Added 12.96%
$1.12B
$3.69 Billion 2.98% of portfolio
80,002
Q4 2024 Added 6.67%
Inhibikase Therapeutics Inc
-
$3.68 Billion 2.97% of portfolio
-
Q4 2024 New
$218M
$3.45 Billion 2.79% of portfolio
324,324
Q4 2024 Added 15.69%
$240M
$3.3 Billion 2.67% of portfolio
125,700
Q4 2024 Reduced 35.57%
$632M
$2.98 Billion 2.4% of portfolio
235,000
Q4 2024 Added 14.26%
$228M
$2.87 Billion 2.32% of portfolio
648,785
Q4 2024 Reduced 35.12%
Surrozen Inc
-
$1.97 Billion 1.59% of portfolio
-
Q4 2024 Added 24.73%
Inovio Pharmaceuticals Inc
-
$1.92 Billion 1.55% of portfolio
-
Q4 2024 New
$150M
$1.91 Billion 1.54% of portfolio
331,900
Q4 2024 New
$33.3M
$1.77 Billion 1.43% of portfolio
274,426
Q4 2024 Added 174.43%
Calcimedica Inc
-
$1.66 Billion 1.34% of portfolio
-
Q4 2024 New
$129M
$1.65 Billion 1.33% of portfolio
663,405
Q4 2024 Reduced 73.02%
$148M
$1.5 Billion 1.21% of portfolio
200,000
Q4 2024 New
$8.71B
$1.23 Billion 0.99% of portfolio
10,000
Q4 2024 Reduced 81.82%
$1.09B
$1.2 Billion 0.97% of portfolio
164,106
Q4 2024 New
$49.2M
$1.18 Billion 0.95% of portfolio
500,000
Q4 2024 Reduced 49.99%
$1.03B
$1.13 Billion 0.91% of portfolio
20,400
Q4 2024 New
$303M
$1.07 Billion 0.86% of portfolio
700,000
Q4 2024 New
$44.6M
$1.03 Billion 0.83% of portfolio
251,049
Q4 2024 Reduced 53.02%
$98.5M
$882 Million 0.71% of portfolio
300,000
Q4 2024 Added 200.0%
$244M
$845 Million 0.68% of portfolio
110,000
Q4 2024 Added 266.67%
$58.9M
$809 Million 0.65% of portfolio
535,805
Q4 2024 New
Kezar Life Sciences Inc
-
$739 Million 0.6% of portfolio
-
Q4 2024 New
Aytu Biopharma Inc
-
$693 Million 0.56% of portfolio
-
Q4 2024 Reduced 18.65%
Kiora Pharmaceuticals Inc
-
$663 Million 0.54% of portfolio
-
Q4 2024 Reduced 0.71%
$34.8M
$673 Million 0.54% of portfolio
700,000
Q4 2024 Added 14.86%
$510M
$618 Million 0.5% of portfolio
182,317
Q4 2024 New
$142M
$570 Million 0.46% of portfolio
160,000
Q4 2024 New
Aprea Therapeutics Inc
-
$491 Million 0.4% of portfolio
-
Q4 2024 Added 8.78%
Acelyrin Inc
-
$417 Million 0.34% of portfolio
-
Q4 2024 New
$81.6M
$345 Million 0.28% of portfolio
250,000
Q4 2024 New
Polypid LTD
-
$315 Million 0.25% of portfolio
-
Q4 2024 Reduced 25.15%
$59.5M
$274 Million 0.22% of portfolio
132,347
Q4 2024 New
$22.3M
$271 Million 0.22% of portfolio
196,732
Q4 2024 New
$272M
$120 Million 0.1% of portfolio
25,000
Q4 2024 New
$11M
$113 Million 0.09% of portfolio
200,000
Q4 2024 New
Abivax Sa
-
$110 Million 0.09% of portfolio
-
Q4 2024 New
Alimera Sciences Inc Cvr
-
$107 Million 0.09% of portfolio
-
Q3 2024 New
Allarity Therapeutics Inc
-
$78.7 Million 0.06% of portfolio
-
Q4 2024 New

Summary

  • Portfolio
  • No. of Stocks 52
  • Current Value $124 Billion
  • Prior Value $158 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 13, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 22 stocks
  • Additional Purchases 13 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 16 stocks
Track This Portfolio

Track Stonepine Capital Management, LLC Portfolio

Follow Stonepine Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonepine Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email